Hussain Alizadeh

7. József Attila Street, 
Pecs, BA, HU 
7. József Attila Street, 
Pecs, BA, HU 

Overview

Hussain Alizadeh practices practicing medicine in Pecs, Hungary.

His clinical expertise encompasses Multiple Myeloma, Non-Hodgkin Lymphoma, Familial Hypertriglyceridemia, Chronic Myelogenous Leukemia (CML), and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 60 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

7. József Attila Street, Pecs, BA 7623, Hungary

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
View 2 Less Clinical Trials

60 Total Publications

Unchanged prevalence and increased severity of anemia from 2019 to 2022 in emergency care outpatients: A cross-sectional study from a tertiary care university hospital of Pécs, Hungary.
Unchanged prevalence and increased severity of anemia from 2019 to 2022 in emergency care outpatients: A cross-sectional study from a tertiary care university hospital of Pécs, Hungary.
Journal: Science progress
Published: June 16, 2026

Frequently Asked Questions about Hussain Alizadeh

Is Hussain Alizadeh a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Hussain Alizadeh is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hussain Alizadeh participate in research or clinical trials?

Yes. Hussain Alizadeh has published 60 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Hussain Alizadeh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Alizadeh's expertise for a condition
ConditionClose
        View All 27 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile